Thermo Fisher Scientific has launched the Thermo Scientific Smart-Vue Pro, a next-generation remote monitoring solution for biotechnology, pharmaceutical, clinical and academic laboratories. The device is designed to enable superior levels of sample protection, workflow efficiencies, asset/cost optimization and regulatory compliance.
With the option for an on-premise or cloud setup, the Thermo Scientific Smart-Vue Pro Remote Monitoring Solution provides real-time, continuous monitoring of critical laboratory equipment parameters and immediately notifies users about off-limit measurements that, if left unattended, could compromise sample safety and integrity. Notifications are delivered by email, text message or phone call, through a secure network, prompting corrective action.
Importantly, the Smart-Vue Pro solution delivers fully traceable data logging and secure user-level access to the complete system functionality at anytime from anywhere with Internet access, facilitating compliance with a wide range of regulatory standards, including 21CFR Part 11 and cGxP.
Operating on the LoRaWAN (Long-Range Wide Area Network) technology, the Smart-Vue Pro solution can simultaneously monitor conditions across several laboratories located on different floors or buildings. The LoRaWAN technology ensures a single receiver can cover up to 2km line of sight in urban areas, eliminating the need to invest in multiple monitoring systems. Scalability is further enhanced through the advanced modular, customizable architecture of the Smart-Vue Pro solution that supports up to four pre-calibrated Smart Digital Sensors. As a result, the system can monitor many pieces of equipment or multiple parameters within one piece of equipment at the same time. Finally, the Smart-Vue Pro solution allows for easy expansion to accommodate additional pieces of equipment without the need for costly upgrades. Overall, this improved scalability results in considerable installation, hardware and maintenance cost savings.
The Smart-Vue Pro solution features an interactive, colour touchscreen that displays data along with visual and audio alarms for at-a-glance monitoring, while enabling simplified and customizable views for an enhanced user experience.
Thermo Fisher Scientific supports the Smart-Vue Pro solution with end-to-end service and support packages to guide users through installation, validation, implementation and maintenance.
The Smart-Vue Pro solution is capable of monitoring temperatures ranging from −200°C to +150°C, relative humidity and dry contact state, with CO2 concentration and differential pressure set to be added to the system’s measurement capabilities in the near future.

• For more information, visit: www.thermofisher.com/smartvuepro

Read more

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, has announced the availability of SARS-CoV-2 neutralizing antibodies derived from individuals infected with COVID-19. The antibodies, originally generated by Fred Hutchinson Cancer Research Center, have been engineered into recombinant formats useful for COVID-19 research and diagnostic development. They are now available to scientists and diagnostic developers worldwide via Absolute Antibody’s online catalogue.
The new antibodies were generated from the blood cells of an infected COVID-19 patient and have shown in a recent study to display neutralizing activity against SARS-CoV-2. Two antibody clones (CV1 and CV30) each bound the SARS-CoV-2 spike glycoprotein, with CV30 also shown to bind the receptor binding domain (RBD) and inhibit the interaction with the host cell receptor ACE2. Both antibodies are now available in a variety of species, isotypes and subtypes designed to extend their usefulness in COVID-19 applications.
Absolute Antibody offers the SARS-CoV-2 antibodies in human formats such as IgG1, IgG3, IgM and IgA, for use in neutralization assays and as serological controls in COVID-19 diagnostic tests. In addition, the antibodies are available in species such as mouse and rabbit for detection applications and co-labelling studies; fragment formats for better tissue penetration and in vivo imaging; and with engineered Fc Silent domains to facilitate research into antibody-dependent enhancement. All antibodies are recombinantly produced for ensured batch-to-batch reproducibility, high purity and low endotoxin levels.
The new neutralizing antibodies join Absolute Antibody’s full collection of engineered coronavirus reagents, including the spike glycoprotein antibody clone CR3022, nucleoprotein antibodies, ACE2 Fc fusion proteins, and anti-human immunoglobulin antibodies for use in diagnostic tests.
Absolute Antibody is also supporting coronavirus research by providing antibody engineering and manufacturing services, including the production of gram quantities of human antibodies sequenced from recovering COVID-19 patients.

• For more information, visit: https://absoluteantibody.com/general/sars-cov-2-neutralizing-antibodies

Read more

ELITechGroup Molecular Diagnostics, a leading global provider of diagnostic testing products, passed a significant milestone early August with the distribution of more than 3.5 million SARS-CoV-2 tests worldwide. The company has also installed more than 500 of its lead diagnostics instrument, the ELITe InGenius polymerase chain reaction (PCR) system, globally, with over a hundred placed since the beginning of the pandemic. The system allows laboratories to reliably detect SARS-CoV2 in only a few hours, as well as conducting parallel testing for other diseases, such as flu, in order to ensure a correct diagnosis.
The ELITe InGenius has been widely used in hospitals and other healthcare settings since 2016, and ELITechGroup was among the first companies to have SARS-CoV-2 tests on a sample-to-result system.
The ELITe InGenius is a fully automated solution that can process 12 samples in parallel to deliver results in less than 2.5 hours. This brings several benefits over centralized high-throughput testing approaches as there is no waiting for a large batch of samples to accumulate before testing, and no delays from sending samples off premises to a central laboratory.
By performing extraction, amplification and result interpretation in one device, the ELITe InGenius replaces the multiple devices needed to perform such tasks separately. Full automation also means there is no need for constant supervision, allowing laboratory staff to perform other valuable work. More importantly, the limited hands-on time helps reduce the risk of infection for users. The instrument is straightforward to use, with only minimal training required from ELITechGroup’s service and support team.
The ELITe InGenius offers the widest molecular diagnostics menu available on a sample-to-result system, with 38 CE-IVD assays dedicated to the unique needs of healthcare settings, be it immunocompromised patient monitoring; detection of respiratory, gastro-intestinal, sexually transmitted or nosocomial infections; meningitis and encephalitis, as well as diagnostics of genetic factors.
Commenting on the advantages of the ELITe InGenius for hospital settings, Dr Anna Paola Callegaro, Virology Area Coordinator and Biobank UOSD Director of ASST Papa Giovanni XXIII – Bergamo (Italy), commented: “The modular configuration of the ELITe InGenius system enables us to carry out molecular virology routine with results on the day. The sample-to-result solution reduces the need for manual intervention by the technician and allows the analysis of multiple viral targets on the same sample, thereby significantly improving the lab’s efficiency.”
Christoph Gaue, ELITechGroup CEO, said the company has expanded their manufacturing capacity to help provide additional ELITe InGenius systems to hospitals and laboratories, globally.
For more information, visit: www.elitechgroup.com
Read more

The Native Antigen Company (now part of LGC’s Clinical Diagnostics Division), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, has introduced its custom contract service to rapidly develop antigen panels for influenza A and B viruses. This new service offers scientists access to high-quality proteins from emerging seasonal and pandemic influenza strains, to support ongoing research and development of diagnostics and vaccines.
The Native Antigen Company provides custom contract services to develop panels of the influenza antigens from a wide range of virus strains and subtypes using its proprietary HEK293 mammalian expression system (VirtuE), which is able to introduce proper protein folding and full glycosylation to closely mimic naturally occurring proteins.
The Company has already used this recombinant protein expression system to successfully develop a range of haemagglutinin and neuraminidase proteins for influenza A and B viruses, both of which spread routinely in humans and are responsible for seasonal flu epidemics each year. Its custom contract service could help researchers working with specific strains of influenza gain rapid access to highly purified proteins to conduct detailed assessments of immune responses with diagnostics, including vaccination responses to particular strains.

• For more information, visit: thenativeantigencompany.com/influenza-services-landing-page

Read more